Pfizer today announced that the Phase 3 study investigating the treatment of inotuzumab ozogamicin met its first primary endpoint of demonstrating a higher complete hematologic remission rate in adult patients with relapsed or refractory CD22-positive acute lymphoblastic leukemia compared to that achieved with standard of care chemotherapy. The Phase 3 study has two primary endpoints, complete hematologic remission rate and overall survival.
http://ift.tt/1DIJNCP
No comments:
Post a Comment